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Background: Research has shown that eligible outpatients with heart failure (HF) and reduced left ventricular ejection fraction (LVEF) frequently 
do not receive guideline-recommended target doses of evidence-based medical therapy.
Methods: IMPROVE HF is a prospective study to improve adherence to guideline-recommended therapies for outpatients with LVEF ≤ 35%. 
A performance improvement intervention was delivered to 167 US cardiology practices. Chart reviews conducted at baseline and 24 months 
post-intervention recorded dose, type, and frequency for ACEI/ARB, β-blockers, and aldosterone antagonists. Changes in absolute and relative 
improvements in target dose for each medication class were analyzed at the practice and patient levels.
Results: A total of 155 of 167 practices completed the study with 15,177 patients available for analysis. Baseline percent of patients treated at 
or above target dose of ACEI/ARB was 38.8%; β-blocker was 23.0%, and aldosterone antagonist was 81.2%. Absolute and relative improvements 
in target dosing of β-blockers at 24 months were 9.9% and 43.0%, respectively, but similar improvements were not evident for ACEI/ARB or 
aldosterone antagonists.
Conclusion: Significant increases in eligible patients treated at or above target doses were achieved only for β-blockers. Additional research 
regarding barriers to use of target doses of medical therapies and tailored interventions may be necessary to improve adherence to guideline-
recommended HF care. 
Patients Receiving Target 
Doses of Therapy
Baseline, n*; % (95% CI) 24 Months, n*, % (95% CI)
Absolute Improvement
Baseline vs 24 Months, %
(95% CI)
Relative Improvement
Baseline vs 24 Months, %
(95% CI)
P-value
ACEI/ARB 
2142/5515; 38.8%
(37.6, 40.1)
2026/5329; 38.0%
(36.7, 39.3)
-0.8%
(-2.7, 1.0)
-2.1%
(-6.8, 2.6)
0.379
Beta-blocker
1254/5452; 23.0%
(21.9, 24.1)
1875/5701; 32.9%
(31.7, 34.1)
9.9%
(8.2, 11.5)
43.0%
(35.8, 50.2)
< 0.001
Beta-blocker subgroups
•
Bisoprolol
•
Carvedilol
•
Metoprolol tartrate
•
Metoprolol succinate
12/36;
33.3%
(17.9, 48.7)
1084/3921; 27.6%
(26.2, 29.0)
53/702;
7.5%
(5.6, 9.5)
105/793;
13.2
(10.9, 15.6)
17/46;
37.0%
(23.0, 50.9)
1637/4110; 39.8%
(38.3, 41.3)
63/476;
13.2%
(10.2, 16.3)
158/1069;
14.8
(12.7, 16.9)
3.6%
(-17.2, 24.4)
12.2%
(10.1, 14.2)
5.7%
(2.1, 9.3)
1.5%
(-1.6, 4.7)
10.9%
(-51.5, 73.2)
44.1%
(36.7, 51.5)
75.3%
(27.4, 123.2)
11.6%
(-12.4, 35.6)
0.733
< 0.001
0.002
0.342
Aldosterone antagonist 
337/415;
81.2%
(77.4, 85.0)
626/796;
78.6%
(75.8, 81.5)
-2.6%
(-7.3, 2.2)
-3.2%
(-9.0, 2.7)
0.287
*Number of patients treated/total number of patients eligible.
**P value is for the relative improvement comparison
